YUMAB GmbH

Braunschweig, United Kingdom

YUMAB GmbH

Braunschweig, United Kingdom
SEARCH FILTERS
Time filter
Source Type

News Article | July 31, 2017
Site: www.prnewswire.com

LONDON, July 31, 2017 /PRNewswire/ -- INTRODUCTION The rising demand of personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody based therapeutics. Antibodies, because of several advantages such as high specificity and targeted approach, are increasingly becoming crucial for the treatment of a number of diseases. In fact, since 2015, more than 20 antibodies have been approved by the USFDA. The growing popularity of antibody based therapeutics is also reflected from the dominance of these biologics in the portfolios of major biopharmaceutical companies. Download the full report: https://www.reportbuyer.com/product/5028029/ At present, the focus of majority of biopharmaceutical companies is on discovering therapeutic antibodies against novel targets. However, discovery of antibodies is a long, arduous and costly process; as a result, there is a growing preference to outsource such operations. Drug developers are partnering with contract research organizations (CROs) that provide antibody discovery services using novel and advanced technologies. Outsourcing enables biopharmaceutical companies / academic institutes accelerate their drug discovery process by leveraging the technical capabilities and expertise of CROs. Additionally, a number of drug developers and academic institutes have obtained rights to access novel antibody discovery platforms from technology providers. As the demand of novel therapeutic antibodies for various disease areas is expected to rise steadily, we are optimistic about the future of the contract research firms that are driving innovation in the drug discovery process. SCOPE OF THE REPORT The 'Antibody Discovery: Services and Platforms, 2017-2027' report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and platform providers. The study presents an in-depth analysis of a diverse set of companies that provide antibody discovery services and / or provide access to their platforms to drug developers. In addition to other elements, the report provides information on the following: - The competitive market landscape and industry analysis with respect to key players along with information on their geographical location, type of business operation, methods used for antibody generation and the purpose of antibody discovery (therapeutic and / or diagnostic). - Elaborate profiles of established / emerging players that offer a wide range of services in the overall antibody discovery process; each profile includes a brief overview of the company, information on its financial and funding details (if available), antibody discovery service portfolio and novel antibody discovery technology / platforms, and a view on its future outlook and strategy. - Most active regions in terms of antibody discovery services and platforms; the report contains schematic representations of world maps that clearly indicate the location of antibody discovery service hubs. - Platform competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of antibody discovery platforms that are available for licensing. - A case study covering detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies such as Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®. - Partnerships that have taken place in the recent past covering research collaborations, service agreements, license agreements, mergers / acquisitions and other deals signed between industry / non-industry stakeholders. The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the antibody discovery services market. We have provided insights on the likely evolution of the market in different regions including North America, Europe, China and rest of the world. In addition, we have provided the likely evolution on the basis of the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (chimeric, humanized and fully human). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 60 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB). RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include: - Annual reports - Investor presentations - SEC filings - Industry databases - News releases from company websites - Government policy documents - Industry analysts' views While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. CHAPTER OUTLINES Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term. Chapter 3 provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, such as polyclonal, monoclonal and bispecific antibodies. Chapter 4 features information on the antibody discovery process and the various antibody discovery methods. It also includes a comparison of the different antibody discovery methods that are available currently. Additionally, the chapter provides insights on the gradual shift in development trends for monoclonal antibodies over the last three decades, from fully murine to fully human variants. Chapter 5 includes a comprehensive landscape of the companies that offer antibody discovery services and / or provide licenses to their antibody discovery platforms. For the antibody discovery service providers, the chapter includes analyses on the basis of their geographical location, type of business operations, methods used for antibody generation, steps involved in antibody discovery and purpose of antibody discovery (therapeutic and / or diagnostic). For antibody discovery platform providers, the chapter provides analysis based on geographical location and antibody generation methods on which the platforms are based. Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs. Chapter 6 provides detailed profiles of some of the players, based in different geographies, which are actively providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial and funding information (if available), details on antibody discovery services and novel antibody discovery technology / platforms, and a view on its future outlook and strategy. Chapter 7 provides detailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, funding instances, financial information (if available), details on antibody discovery technology / platforms and a view on its future outlook and strategy. The chapter also presents 2 X 2 matrices, comparing competitiveness and supplier power of the antibody discovery platforms. Chapter 8 presents a comprehensive view on how the antibody discovery services market is likely to grow over the next ten years. We have segregated the financial opportunity on the basis of different regions (North America, Europe, China and rest of the world), the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (murine, chimeric, humanized and fully human). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. The chapter also presents insightful 2 X 2 matrices to highlight the market share and market attractiveness derived from the current and likely future state of the market. Due to uncertainties surrounding some of the assumptions within our forecast model, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios. Chapter 9 features an elaborate discussion and analysis on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. Chapter 10 provides detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies. The antibodies for which details on discovery process and method are provided include Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®. Chapter 11 presents insights from the survey conducted for this study. We invited over 60 stakeholders involved in providing antibody discovery services and platforms. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential. Chapter 12 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this market in the short and long term. Chapter 13 is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB). Chapters 14 is an appendix, which provides tabulated data and numbers for all the figures in the report. Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report. EXAMPLE HIGHLIGHTS 1. During the course of our study, we identified more than 60 companies that offer antibody discovery services. Majority (more than 80%) of these antibody discovery service providers are located in North America and EU. Examples of the players based in these regions include (in alphabetical order) Adimab, Aragen Bioscience, Antibody Solutions, Evotec, GenScript, Integral Molecular, ModiQuest Research and PX'Therapeutics. 2. It is worth highlighting that a number of start-ups have entered this domain to provide contract research services; examples include (in alphabetical order) Ab Studio, Abveris Antibody, AffinityImmuno, ChemBio Discovery Solutions, G&P Biosciences, HiFiBiO, OriMAbs, Panoply Bio and Specifica. 3. CROs offer antibody discovery services by deploying a variety of methods such as library based (phage display, yeast display and mammalian display), hybridoma, transgenic animal based and single cell based methods. During our research, we observed that a vast majority of companies (31) offer antibody discovery services by using library based methods. This is followed by companies that use hybridoma method (27), single cell based methods (13) and transgenic animal based methods (11). 4. Companies that have developed novel antibody drug discovery platforms are providing access / non-exclusive licenses of their proprietary platforms to drug developers, CROs and academic institutes. During the course of our study, we identified more than 20 such platform providers. Around 40% of the antibody discovery platform providers are headquartered in North America, 36% of companies are based in Europe while the remaining (24%) are located in the Asia Pacific region. 5. Majority (13) of the platforms available for licensing are library based; examples include Abtracer™, ADAPT™, ADLib® library, mAbLogix™ and n-CoDeR® antibody library. There are seven transgenic animal based platforms that are available for licensing; these include AlivaMab™ Mouse, Kymouse™ platform, OmniAb® platforms and TRIANNI Mouse platform. 6. A number of stakeholders in the field of antibody discovery have entered into collaborations with CROs and / or technology providers. We came across 172 deals that have been signed during the period 2011-2017. Majority (~50%) of the partnerships in this domain are research collaborations; this highlights the fact that extensive research is being conducted to discover novel therapeutic antibodies. Technology licensing is the second most popular partnership model in this field, capturing 32% share. Prominent contract service providers that have entered into multiple partnerships include Adimab, Crystal Biosciences, MAB Discovery, AbCellera and Abzena. 7. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to witness continuous growth in the coming decade. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; we believe that China is likely to grow at faster rate (annualized rate of 8.9%) as compared to other regions in the coming decade. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate (annualized rate of 6.6%) as compared to the established methods such as phage display and hybridoma methods. Download the full report: https://www.reportbuyer.com/product/5028029/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com


Frenzel A.,YUMAB GmbH | Frenzel A.,TU Braunschweig | Schirrmann T.,YUMAB GmbH | Hust M.,TU Braunschweig
mAbs | Year: 2016

Over the last 3 decades, monoclonal antibodies have become the most important class of therapeutic biologicals on the market. Development of therapeutic antibodies was accelerated by recombinant DNA technologies, which allowed the humanization of murine monoclonal antibodies to make them more similar to those of the human body and suitable for a broad range of chronic diseases like cancer and autoimmune diseases. In the early 1990s in vitro antibody selection technologies were developed that enabled the discovery of “fully” human antibodies with potentially superior clinical efficacy and lowest immunogenicity. Antibody phage display is the first and most widely used of the in vitro selection technologies. It has proven to be a robust, versatile platform technology for the discovery of human antibodies and a powerful engineering tool to improve antibody properties. As of the beginning of 2016, 6 human antibodies discovered or further developed by phage display were approved for therapy. In 2002, adalimumab (Humira®) became the first phage display-derived antibody granted a marketing approval. Humira® was also the first approved human antibody, and it is currently the best-selling antibody drug on the market. Numerous phage display-derived antibodies are currently under advanced clinical investigation, and, despite the availability of other technologies such as human antibody-producing transgenic mice, phage display has not lost its importance for the discovery and engineering of therapeutic antibodies. Here, we provide a comprehensive overview about phage display-derived antibodies that are approved for therapy or in clinical development. A selection of these antibodies is described in more detail to demonstrate different aspects of the phage display technology and its development over the last 25 years. © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC © André Frenzel, Thomas Schirrmann, and Michael Hust.

Loading YUMAB GmbH collaborators
Loading YUMAB GmbH collaborators